- $352.54m
- $363.38m
Annual cashflow statement for Cytodyn, fiscal year end - May 31st, USD millions except per share, conversion factor applied.
2022 May 31st | 2023 May 31st | 2024 May 31st | 2025 May 31st | 2026 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -211 | -79.8 | -49.8 | 3.75 | -42.7 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 137 | 35.1 | 27.2 | 3.64 | 3.26 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.78 | 19.4 | 11.7 | -16.2 | 22.2 |
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -77.7 | -25.1 | -11 | -8.77 | -17.3 |
| Capital Expenditures | 0 | — | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | 0 | — | — | 0 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0 | 0 | — | — | 0 |
| Financing Cash Flow Items | 5.39 | 2.81 | 0.3 | 10.4 | 0.874 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 48 | 29.9 | 11.7 | 10.9 | 17.2 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -29.7 | 4.82 | 0.766 | 2.09 | -0.051 |